The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-R) and its related congeners such as pros-linked ribotide and riboside. The invention is based on the discovery that IAA-RP and to a lesser extent IAA-P bind with a high affinity to imidazoline receptors. Antibodies to IAA-RP, IAA-R are additionally provided, as well as screening methods for identification of compounds that either promote or antagonize the activity of IAA-RP, IAA-R and its related congeners. The invention further relates to diagnostic and prognostic methods for detection of abnormalities in levels or activity of IAA-RP and IAA-R. The invention encompasses treatment of disorders related to the imidazoline system, including hypertension, glaucoma, psychiatric (e.g., depression), neurological (e.g., motor disorders, neurodegenerative disorders), diabetes and disorders related to platelet aggregation.
本发明涉及调节
咪唑啉受体活性的方法和组合物。特别是,本发明涉及包含
咪唑乙酸-核苷酸(
IAA-RP)、
咪唑乙酸-核苷酸(
IAA-R)及其相关同系物,如亲链核苷酸和核苷酸的药物组合物。本发明基于以下发现:
IAA-RP 以及在较小程度上
IAA-P 与
咪唑啉受体结合的亲和力很高。本发明还提供了
IAA-RP、
IAA-R 的
抗体,以及鉴定促进或拮抗
IAA-RP、
IAA-R 及其相关同系物活性的化合物的筛选方法。本发明还涉及检测
IAA-RP 和
IAA-R
水平或活性异常的诊断和预后方法。本发明包括治疗与
咪唑啉系统有关的疾病,包括高血压、青光眼、精神疾病(如抑郁症)、神经系统疾病(如运动障碍、神经退行性疾病)、糖尿病和与血小板聚集有关的疾病。